06:03 AM EDT, 09/18/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday its injectable Ozempic was linked to a 23% lower risk of heart attack, stroke, and death compared with dulaglutide in US Medicare patients with type 2 diabetes and cardiovascular disease.

The real-world Reach study analyzed nearly 60,000 patients aged 66 and older with atherosclerotic cardiovascular disease, the company said.

Ozempic was also associated with a 26% lower risk of death versus dulaglutide, Novo Nordisk ( NVO ) said.

In addition, the company also said the drug demonstrated a 25% reduction in a composite measure of heart attack, stroke, hospitalizations for unstable angina or heart failure, and death.

Shares of the company were up over 5% in recent Thursday premarket activity.

Price: 61.22, Change: +3.02, Percent Change: +5.19